Features
Why Choose BONTAC?
Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NADH manufacturer | NADH and NAD+ are a pair of redox pairs in cells, NADH is the reduced form of coenzyme 1NAD, and NAD+ is its oxidized form. In redox reactions, NADH acts as a donor of hydrogen and electrons, and NAD+ acts as an acceptor of hydrogen and electrons, participating in physiological processes such as respiration, photosynthesis, and alcohol metabolism. They participate in life activities as coenzymes of many oxidation-reduction reactions in organisms and transform each other. Under anaerobic conditions, glucose metabolism produces very little ATP, while under aerobic conditions, NADH or FADH2 produced through glycolysis and tricarboxylic acid cycle can produce a large amount of ATP through oxidative phosphoric acid reaction. The amount of NADH is directly related to the amount of ATP produced, the more NADH each cell contains, the more energy it produces. Organs that require more energy will contain (or require) higher amounts of NADH.
Featured Products
Collection about BONTAC
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
Our updates and blog posts
The Significance of NAD+ in Intestinal Senescence Caused by Elevated mtDNA Mutations
1.Introduction The senescence in mammals is generally concomitant with the dysregulation of intestinal homeostasis and the accumulation of mitochondrial DNA (mtDNA) mutations. High-burden mtDNA mutations lead to NAD+ depletion and activate the transcription factor ATF5-dependent UPRmt, which in turn promotes and exacerbates the intestinal senescence phenotype. By supplementation with the NAD+ precursor NMN, this intestinal senescence phenotype can be rescued to some extent, as evidenced by the recovery of intestinal organoid differentiation and the increased number of intestinal stem cells. 2. NAD+ depletion during intestinal senescence caused by mtDNA mutations There is impairment of NADH/NAD+ redox in Mut/Mut*** intestines, as manifested by the enriched NADH dehydrogenase complex assembly pathway. Through transfection of intestinal crypt cells with SoNar (a NADH/NAD+ sensor), a higher NADH/NAD+ ratio is observed in Mut/Mut*** mice, hinting the perturbed redox potential. Likewise, following transfection of intestinal crypt cells with FiNad (a NAD+ sensor), less NAD+ content is discovered in the Mut/Mut*** cells. All of these findings mirror NAD+ depletion in the intestinal senescence triggered by mtDNA mutations. Note: mtDNA mutations are classified into four types: negligible (WT/WT), low (WT/WT*), moderate (WT/Mut**) and high (Mut/Mut***). 3. The link between mtDNA mutation content and physiological intestinal senescence The small intestine of aged mouse intestine is characterized by decreased intestinal crypt number, increased villus length, higher expression of CDKN1A/p21 (a well-known senescence marker) and shorter telomere length, which is accompanied by accumulation of mtDNA mutations, primarily low-frequency (less than 0.05) point mutations. 4. LONP1 protein as a candidate marker for intestinal senescence caused by accumulated mtDNA mutations Mitochondrial unfolded protein response (UPRmt) is activated by a variety of mitochondrial stresses, including protein imbalances between mitochondria and the nucleus as well as impaired mitochondrial protein transport. The hallmarks of UPRmt are increased protein expression levels of LONP1, HSP60 and ClpP. Noteworthily, only LONP1 protein is specifically upregulated in senescent UPRmt activation triggered by accumulated mtDNA mutations, which may be a candidate biomarker for intestinal senescence. 5. The role of NAD+ in intestinal senescence induced by elevated mtDNA mutations. NAD+ repletion in vivo alleviates the small intestine senescent phenotypes caused by mtDNA mutation burden, and rescues the decreased colony formation efficiency in Mut/Mut*** intestinal organoids. NAD+-dependent UPRmt triggered by mtDNA mutations regulates intestinal senescence. These data further indicate that NAD+ depletion functions as a key mediator of the intestinal senescence induced by accumulated mtDNA mutations. 6. The role of NAD+ in the signal pathways regulating intestinal senescence caused by increased mtDNA mutations NAD+ repletion rescues the Foxl1 downregulation and Notch1 upregulation in Mut/Mut*** mice, suggesting that mtDNA mutation burden can regulate the function or number of niche cells through NAD+ depletion. In addition, NAD+ depletion caused by increased mtDNA mutation burden induces the decline of LGR5-positive intestinal cells via impairment of the Wnt/β-catenin pathway. 7. Conclusion NAD+ repletion is significant for the regulation of intestinal homeostasis, playing a critical role in rescuing the intestinal senescence phenotype caused by accumulated mtDNA mutations. Reference Yang, Liang et al. “NAD+ dependent UPRmt activation underlies intestinal aging caused by mitochondrial DNA mutations.” Nature communications vol. 15,1 546. 16 Jan. 2024, doi:10.1038/s41467-024-44808-z About BONTAC BONTAC is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. BONTAC has over 160 domestic and foreign patents, leading the industry of coenzyme and natural products. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and NMN. High quality and stable supply of products can be ensured here. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
Is stevioside a sugar reducer or a health killer？
1. Introduction On July 2023, the World Health Organization (WHO) has classified the soda sweetener aspartame as a possible carcinogen, but said that aspartame is safe to consume within a daily limit of 40 milligrams per kilogram of a person’s body weight according to the latest assessment results regarding the impacts of the non-sugar sweetener aspartame upon the health. How about another sweetener stevioside? Is stevioside a sugar reducer or a health killer? 2. Current situation on stevioside Stevioside (also termed stevia glycoside) has been regarded as “the third largest source of natural sugar across the world” by virtue of its low calorie, high sweetness, good stability and low price, which is widely used in medicine, daily chemicals, beverage, food, brewing and other industries. 3. Regulatory application and control of stevioside The aforementioned report of WHO on the possible carcinogenesis of soda sweetener aspartame is based on high intake. An adult weighing 70 kilograms or 154 pounds would have to drink more than 9 to 14 cans of aspartame-containing soda daily to exceed the limit and potentially face health risks. There is no need to be worry about the risk of carcinogenesis in the case of healthy intake. The same situation is applicable to another sweetener stevioside. Stevioside is approved to be sweetener in food in countries like Mainland China, Japan, Korea, Australia, New Zealand, the USA and European Union. In China, there are detail specifications on the food additive stevioside (GB 2760-2014). 4. The therapeutic properties of stevioside 4.1 Antitumor effect Stevioside can be applied as a valuable chemotherapy candidate to be further investigated for cancer therapy. The activity of the well-known tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), is successfully inhibited with stevioside in a murine skin-cancer model. In addition, stevioside can reduce mammary adenoma incidence in F344 rats. 4.2 Anti-hypertensive activity The hypotensive effect observed in rats after chronic oral administration (30 days) of 2.67 g stevia leaves/day has been confirmed in spontaneously hypertensive rats. In that murine model, stevioside (100 mg/kg; i.v.) is able to reduce blood pressure with no change in serum epinephrine, norepinephrine, or dopamine levels. 4.3 Anti-diabetics In diabetic rats, stevioside (0.2 g/kg; i.v. administration) decreases glucose blood levels, yet increases insulin responses and reactions to an intravenous glucose tolerance test (IVGT). Also, stevioside enhances insulin levels above basal during the IVGT, without altering blood glucose response, in normal rats, hinting its potential as a drug candidate for type 2 diabetes. 4.4 Inhibition of pathogenic bacteria Stevioside has demonstrated antibacterial action on various foodborne pathogenic bacteria, including Escherichia coli, a wellknown etiologic agent of severe diarrhea. Regarding antiviral properties, stevioside seems to impede binding of rotavirus to host cells. Rotavirus is commonly associated with pediatric gastroenteritis. 4.5 Anti-inflammatory property In lipopolysaccharide (LPS)-stimulated THP1 cells, stevioside (1mM) inhibits NF-κB. Moreover, stevioside prevents in vitro upregulation of genes involved in liver inflammation. In addition, silico assays demonstrate its antagonistic action in two proinflammatory receptors: tumor necrosis factor receptor (TNFR)-1 and Toll-like receptor (TLR)-4-MD2. 4.6 Antioxidant capability The antioxidant effects of stevioside and rebaudioside A have been confirmed in a fish model, both of which effectively control lipoperoxidation and protein carbonylation. Furthermore, stevioside prevents oxidative DNA damage in the livers and kidneys of a type 2 diabetes murine model. 5 Conclusion As long as the intake is properly controlled, stevioside can be very useful. Stevioside holds a great promise in the clinical treatment and daily health care. Reference Orellana-Paucar A. M. (2023). Steviosides from Stevia rebaudiana: An Updated Overview of Their Sweetening Activity, Pharmacological Properties, and Safety Aspects. Molecules (Basel, Switzerland), 28(3), 1258. https://doi.org/10.3390/molecules28031258 BONTAC Stevioside Reb-D product features and advantages BONTAC possesses the international application and authorized patents on Stevioside Reb-D (US11312948B2 & ZL2018800019752), where the product quality (purity and stability) can be better ensured. Disclaimer BONTAC shall hold no responsibility for any claims arising directly or indirectly from your reliance on the information and material on this website.
Congratulation! BONTAC gains four more honors in health industry
Introduction On March 28, 2024, Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 is held in Shenzhen, China. By virtue of the technical innovation in synthetic biology, far-reaching industry impact and positive commitment to social responsibility, BONTAC has been awarded 4 more honors in the heath industry, namely the "The Benchmarking Enterprise of Shenzhen Health Industry in 2023", "The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", "Special Contribution Award for Shenzhen Health Industry in 2023" and "The Excellent Case in Shenzhen Health Industry Development Report (2022)". About Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 This conference is organized by Shenzhen Health Industry Alliance, Shenzhen Association for the Development & Promotion of Health Industry and Shenzhen Health Care Association, aiming to award and recognize the paragons in the health industry who make great contributions with their practical actions. They represent the top level and mainstream of Shenzhen in health industry. Evaluation criteria for two of the awards As for “The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", one should be equipped with: * Market share, brand impact and technical innovation ability * Explicit goal, customer demand and operation means * Leading technology, products or services * Management team with abundant experience and professional ability For the Benchmarking Enterprise of Shenzhen Health Industry in 2023, the selected enterprises should have: * Certain industry impacts * Achievement in scientific innovation, intellectual property, etc. * Active participation in the drafting of international/national/industry standard * An efficient and professional team * Positive commitment to the social responsibility Professor Zhang’s speech in round-table dialogue Professor Zhang, the chief scientist and founder in BONTAC, has been invited to participate in the round-table dialogue themed by “Digitization Empowers Nutrition and Health”. She shares profound and unique insights upon the research and practice of coenzyme raw materials in the field of precise nutrition. “BONTAC realizes the efficient synthesis and precise application of coenzyme raw materials in the fields such as food, agriculture and animal nutrition through deep integration of big data with AI technology”, Professor Zhang said. “We not only focus on the extensive use of coenzyme raw materials, but also emphasize their safety and function, with the purpose of satisfying everyone's demand on precise nutrition as well as promoting the continuous innovation and development of the health industry. Novel trend towards health industry Under the guidance of “Health China” strategy, there is an increasing trend towards to the deep integration of digital industry with health industry in current society. The reform of digital technology opens up unprecedented opportunities for the health industry, driving the intelligence, precision and personalization of health. In Shenzhen, a new blueprint for the high-quality development of “20+8” industry clusters (top 20 strategic emerging industrial clusters and 8 industries of the future) has been plotted in 2023. With the continuous optimization of industry structure, the health industry in Shenzhen has been developed rapidly, which infuses new energy for the economy and provides solid support for the citizen’s health and well-being. BONTAC as a driver of health and well-being BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, who adheres to adopt the innovation-driven scientific strategy, with more than 170 invention patents, making great contributions to the health industry. Strikingly, a independent platform for directed evolution has been established in BONTAC, where premium enzyme species can be screened by AI to provide strong support for the production of high-quality coenzyme raw materials, driving the integration of digital industry with health industry. In 2024, BONTAC will continue to stick to our mission of “Green Bio-Tech, Healthier and Better Life!” and actively respond to the appeal in “Outline of the Program for Health China 2030”, promoting the deep integration of synthetic biology with health industry and constructing a better health service system.